Incyte Rises Most in Five Years on Pancreatic Cancer Trial Data (Businessweek)
Incyte Corporation (NASDAQ:INCY) rose the most in more than five years after the company said its leukemia drug helped a subgroup of patients with advanced pancreatic cancer in a mid-phase clinical trial. Incyte jumped 32 percent to $35.75 at 1:09 p.m. New York time, for its biggest intraday increase since January 2008. Forty-two percent of patients who were identified as most likely to benefit from the medicine, Jakafi, survived six months compared with 11 percent on placebo, Wilmington, Delaware-based Incyte Corporation (NASDAQ:INCY) said today in a statement.
Diamond Foods to settle investor lawsuit for about $100 million (Reuters)
Diamond Foods, Inc. (NASDAQ:DMND) agreed to settle an investor lawsuit related to an accounting scandal for about $100 million, much less than the damages estimated by the lead plaintiff. The Emerald Nuts and Kettle Chips maker, whose shares rose 20 percent, also forecast higher-than-expected fourth-quarter sales. The company said it will pay $11 million in cash and issue 4.45 million common shares to a fund to settle the lawsuit involving improper accounting of payments to walnut farmers.
Stock Updates on Organovo Holdings Inc (NYSEMKT: ONVO) (SBWire)
Organovo Holdings Inc (NYSEMKT:ONVO) is up by 3.44 percent at the moment, trading at $6.31 per share, the stock entered the market today at $6.20 per share. Organovo Holdings Inc has traded 1.65 million shares till midday, whereas the average traded volume stands at 4.12 million shares per day. The company at the present is trading at a market capitalization of $480.46 million and holds 76.51 million shares outstanding.
Incyte Corp. Rating Reiterated by Canaccord Genuity (INCY) (Watch List News)
Incyte Corporation (NASDAQ:INCY)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity in a note issued to investors on Wednesday, American Banking News reports. They currently have a $38.00 price target on the stock, up from their previous price target of $31.00. Canaccord Genuity’s price objective would indicate a potential upside of 40.74% from the company’s current price.
Diamond Foods Given New $24.00 Price Target at DA Davidson (DMND) (The Utah People’s Post)
Research analysts at DA Davidson hoisted their price target on shares of Diamond Foods, Inc. (NASDAQ:DMND) from $20.00 to $24.00 in a report released on Wednesday, ARN reports. DA Davidson’s price objective suggests a potential upside of 25.46% from the stock’s previous close. Shares of Diamond Foods traded up 18.40% on Wednesday, hitting $22.65. 1,358,295 shares of the company’s stock traded hands. Diamond Foods, Inc. (NASDAQ:DMND) has a one year low of $12.85 and a one year high of $22.77.